Incannex to Launch FDA-Approved Psilocybin Trial for Anxiety Disorder in US and UK
Portfolio Pulse from Benzinga Newsdesk
Incannex Healthcare Inc. (NASDAQ: IXHL) has received FDA approval to conduct a Phase 2 clinical trial for its psilocybin pharmaceutical formulation, PSX-001, in patients with generalized anxiety disorder in the US and UK. The trial, PsiGAD2, will involve 94 patients and aims to measure changes in anxiety levels using the HAM-A score.
August 05, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Incannex Healthcare Inc. has received FDA approval to conduct a Phase 2 clinical trial for its psilocybin drug PSX-001 in the US and UK, targeting generalized anxiety disorder.
FDA approval for a Phase 2 clinical trial is a significant milestone for Incannex, potentially boosting investor confidence and stock price. The trial's success could lead to further advancements and market opportunities for the company.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100